The FDA granted orphan drug designation to zavabresib, an investigational therapy for the treatment of myelofibrosis, a rare ...
Designation highlights significant unmet medical needAUSTIN, Texas, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ...
Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due to ...
The FDA has granted orphan drug designation (ODD) to LP-284, a next-generation acylfulvene small molecule, for the treatment ...
Pharmaceutical Technology on MSN
Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis
CK0804 is an allogeneic, off‑the‑shelf Treg cell therapy.
The FDA designates ARB1002 as an orphan drug, highlighting its potential as a novel treatment for pancreatic cancer amid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback